Trial reportDrug design, development and therapy2026
Effects of Liposomal Bupivacaine for Superficial Parasternial Intercostal Plane Block on Postoperative Stress and Analgesia in Patients Undergoing Median Sternotomy: A Prospective, Randomized, Double-Blind Trial.
Trial report in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Liposomal bupivacaine may provide prolonged postoperative analgesia, but its efficacy in median sternotomy remains underexplored. This study evaluated whether liposomal bupivacaine for superficial parasternal intercostal plane (SPIP) block improves postoperative analgesia and reduces surgical stress in patients undergoing median sternotomy. Methods: In this prospective, randomized, double-blind controlled trial, 44 patients undergoing elective median sternotomy under cardiopulmonary bypass were randomized to receive SPIP block with either liposomal bupivacaine or ropivacaine. Primary outcomes were visual analog scale (VAS) pain scores within 72 h postoperatively and serum levels of stress markers, including angiotensin II (Ang-II) and interleukin-6 (IL-6). Secondary outcomes included patient-controlled intravenous analgesia boluses, postoperative nausea and vomiting, extubation time, intensive care unit stay, Quality of Recovery-15 (QoR-15) scores, and complications. Results: Compared with the ropivacaine group, the liposomal bupivacaine group showed significantly lower VAS pain scores from 18 to 72 h postoperatively (P < 0.05). Although Ang-II and IL-6 levels increased postoperatively in both groups, concentrations were significantly lower in the liposomal bupivacaine group (P < 0.01). Patients receiving liposomal bupivacaine required fewer analgesic boluses, had shorter intensive care unit stays, faster postoperative recovery, lower incidence of postoperative nausea and vomiting, and significantly improved QoR-15 scores (all P < 0.05). No significant differences were observed in extubation time, hospital stay, or hospitalization costs. No block-related complications were observed. Conclusion: Liposomal bupivacaine for SPIP block improved analgesia up to 72 hours after surgery, may attenuate the surgical stress response, and could promote early recovery in patients undergoing median sternotomy under cardiopulmonary bypass. Trial Registration: Chinese Clinical Trial Registry (ChiCTR2400091199).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.